Compile Data Set for Download or QSAR
Report error Found 634 Enz. Inhib. hit(s) with Target = 'Capsid protein'
TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324403(US10189835, Compound 434)
Affinity DataEC50: <100nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324405(US10189835, Compound 561)
Affinity DataEC50: <100nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324406(US10189835, Compound 587)
Affinity DataEC50: <1.00E+3nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324408(US10189835, Compound 599)
Affinity DataEC50: <100nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324409(US10189835, Compound 795)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324410(US10189835, Compound 796)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324411(US10189835, Compound 798)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324412(US10189835, Compound 800)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324413(US10189835, Compound 803)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324415(US10189835, Compound 805)
Affinity DataEC50: <100nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324416(US10189835, Compound 594)
Affinity DataEC50: <100nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324417(US10189835, Compound 595)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324418(US10189835, Compound 600)
Affinity DataEC50: <100nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324419(US10189835, Compound 695)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324421(US10189835, Compound 697)
Affinity DataEC50: <1.00E+3nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324422(US10189835, Compound 698)
Affinity DataEC50: <100nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324423(US10189835, Compound 699)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324424(US10189835, Compound 828)
Affinity DataEC50: <100nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324424(US10189835, Compound 828)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324425(US10189835, Compound 910)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324426(US10189835, Compound 912)
Affinity DataEC50: <500nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM324427(US10189835, Compound 937)
Affinity DataEC50: <100nMAssay Description:HBV replication inhibition by the compounds of this invention could be determined in cells infected or transfected with HBV, or cells with stably int...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2019
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM472915(US10836769, Example 1)
Affinity DataEC50:  2.5nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM472932(US10836769, Example 2)
Affinity DataEC50:  4.80nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM472982(US10836769, Example 3)
Affinity DataEC50:  2.30nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM472987(US10836769, Example 4)
Affinity DataEC50:  7.5nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM472993(US10836769, Example 5)
Affinity DataEC50:  43.6nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473000(US10836769, Example 6)
Affinity DataEC50:  14nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473001(5-(2-((3,3-difluoro-1-(1-methyl-1H-1,2,3-triazol-5...)
Affinity DataEC50:  17.9nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473019(US10836769, Example 8)
Affinity DataEC50:  4.70nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473022(5-(2-((3,3-difluoro-14(2-methyl-2H-1,2,3-triazol-4...)
Affinity DataEC50:  5.80nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473023(5-(2(3,3-difluoro-1-(1-methyl-1H-1,2,3-triazol-4-y...)
Affinity DataEC50:  33.2nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473024(US10836769, Example 11)
Affinity DataEC50:  71.2nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473025(US10836769, Example 12)
Affinity DataEC50:  93.6nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473026(US10836769, Example 13)
Affinity DataEC50:  8.5nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473027(US10836769, Example 14)
Affinity DataEC50:  2.60nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473028(US10836769, Example 15)
Affinity DataEC50:  5.20nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473029(US10836769, Example 16)
Affinity DataEC50:  1.80nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473030(US10836769, Example 17)
Affinity DataEC50:  4.10nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473031(US10836769, Example 18)
Affinity DataEC50:  2.40nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473032(US10836769, Example 19)
Affinity DataEC50:  20.2nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473033(US10836769, Example 20)
Affinity DataEC50:  503nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473034(US10836769, Example 21)
Affinity DataEC50:  3.90nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473035(US10836769, Example 22)
Affinity DataEC50:  31.5nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473036(US10836769, Example 23)
Affinity DataEC50:  31.8nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473037(US10836769, Example 24)
Affinity DataEC50:  177nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473038(US10836769, Example 25)
Affinity DataEC50:  1.90nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473039(US10836769, Example 26)
Affinity DataEC50:  20.6nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473041(US10836769, Example 27)
Affinity DataEC50:  23nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Novira Therapeutics

US Patent
LigandPNGBDBM473042(US10836769, Example 28)
Affinity DataEC50:  294nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

Displayed 1 to 50 (of 634 total ) | Next | Last >>
Jump to: